Cargando…

A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors

Undifferentiated carcinoma of the bladder is a rare malignancy with a poor prognosis. We present the case of an 81-year-old woman complaining of bladder irritation. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a bulky bladder tumor, which was diagnosed as cT4aN0M0. A transu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakane, Wataru, Naito, Yushi, Morishita, Koya, Matsuo, Kazuna, Ishida, Shohei, Matsukawa, Yoshihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748333/
https://www.ncbi.nlm.nih.gov/pubmed/36544596
http://dx.doi.org/10.18999/nagjms.84.4.865
_version_ 1784849803012734976
author Nakane, Wataru
Naito, Yushi
Morishita, Koya
Matsuo, Kazuna
Ishida, Shohei
Matsukawa, Yoshihisa
author_facet Nakane, Wataru
Naito, Yushi
Morishita, Koya
Matsuo, Kazuna
Ishida, Shohei
Matsukawa, Yoshihisa
author_sort Nakane, Wataru
collection PubMed
description Undifferentiated carcinoma of the bladder is a rare malignancy with a poor prognosis. We present the case of an 81-year-old woman complaining of bladder irritation. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a bulky bladder tumor, which was diagnosed as cT4aN0M0. A transurethral resection of the bladder tumor revealed pT2 or higher urothelial carcinoma. The patient underwent total cystectomy with an ileal conduit diversion. Histological examination revealed a primary undifferentiated bladder carcinoma with a sarcoma component, pT3aN0M0. Postoperative adjuvant chemotherapy with gemcitabine plus carboplatin was administered. However, this regimen was discontinued after one course due to significant myelosuppression. Four months after total cystectomy, a pelvic tumor with suspected local recurrence was detected on CT. The patient was diagnosed with recurrent undifferentiated carcinoma with a sarcoma component by a transperineal ultrasound-guided biopsy. Local radiation therapy and immunotherapy with immune checkpoint inhibitors were prescribed. After three courses of immunotherapy with pembrolizumab, the primary tumor disappeared. Upon continuing immune checkpoint inhibitor treatment, the patient has maintained a complete response without tumor recurrence in the following six months.
format Online
Article
Text
id pubmed-9748333
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nagoya University
record_format MEDLINE/PubMed
spelling pubmed-97483332022-12-20 A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors Nakane, Wataru Naito, Yushi Morishita, Koya Matsuo, Kazuna Ishida, Shohei Matsukawa, Yoshihisa Nagoya J Med Sci Case Report Undifferentiated carcinoma of the bladder is a rare malignancy with a poor prognosis. We present the case of an 81-year-old woman complaining of bladder irritation. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a bulky bladder tumor, which was diagnosed as cT4aN0M0. A transurethral resection of the bladder tumor revealed pT2 or higher urothelial carcinoma. The patient underwent total cystectomy with an ileal conduit diversion. Histological examination revealed a primary undifferentiated bladder carcinoma with a sarcoma component, pT3aN0M0. Postoperative adjuvant chemotherapy with gemcitabine plus carboplatin was administered. However, this regimen was discontinued after one course due to significant myelosuppression. Four months after total cystectomy, a pelvic tumor with suspected local recurrence was detected on CT. The patient was diagnosed with recurrent undifferentiated carcinoma with a sarcoma component by a transperineal ultrasound-guided biopsy. Local radiation therapy and immunotherapy with immune checkpoint inhibitors were prescribed. After three courses of immunotherapy with pembrolizumab, the primary tumor disappeared. Upon continuing immune checkpoint inhibitor treatment, the patient has maintained a complete response without tumor recurrence in the following six months. Nagoya University 2022-11 /pmc/articles/PMC9748333/ /pubmed/36544596 http://dx.doi.org/10.18999/nagjms.84.4.865 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Case Report
Nakane, Wataru
Naito, Yushi
Morishita, Koya
Matsuo, Kazuna
Ishida, Shohei
Matsukawa, Yoshihisa
A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
title A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
title_full A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
title_fullStr A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
title_full_unstemmed A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
title_short A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
title_sort case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748333/
https://www.ncbi.nlm.nih.gov/pubmed/36544596
http://dx.doi.org/10.18999/nagjms.84.4.865
work_keys_str_mv AT nakanewataru acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT naitoyushi acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT morishitakoya acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT matsuokazuna acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT ishidashohei acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT matsukawayoshihisa acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT nakanewataru caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT naitoyushi caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT morishitakoya caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT matsuokazuna caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT ishidashohei caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors
AT matsukawayoshihisa caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors